IDEA TESTS GROUP

IDEA Clinic

Clinical study final report

Assessment of anti-acneic potential, of the clinical and dermatological tolerance and acceptability of a cosmetic product after a 28-day period of application under normal conditions of use – in use test under dermatological control on 30 volunteers

Investigational product	:	ABICARE CREME
IDEA Tests study number	:	233495
Investigator	:	Caterina PAHOMI, Dermatologist
Date of beginning of the study	:	16/09/2019
Date of end of the study	:	15/10/2019
Date of report	:	07/11/2019
Version	:	1

Sponsor
REPOLAR PHARMACEUTICALS OY
Suomalaistentie 7
02270 ESPOO
FINLAND

Place of study
CTI
Street Iuliu Teodori, Number (no.) 1, Sector 5
050496 BUCHAREST
ROMANIA

CONTENTS

AUTHENTICITY OF THE RESULTS 3
1. PURPOSE OF THE STUDY 4
2. INVESTIGATIONAL PRODUCT 4
2.1. Characteristics 4
2.2. Instructions for use during the study 4
3. EXPECTED POPULATION BY PROTOCOL 4
3.1. Number of volunteers to be included 4
3.2. Inclusion criteria 5
3.3. Non-inclusion criteria 5
3.4. Study imperatives 5
4. METHODOLOGY 5
4.1. Visit on D1 (V1) 6
4.2. Visit on D28 (V2) 6
5. RESULTS AND ANALYSIS 6
5.1. Experimental conditions 6
5.1.1. Population analysed 6
5.1.2. Protocol deviation 7
5.2. Results - discussion 7
5.2.1. Assessment of anti-acneic potential 7
5.2.2. Clinical and dermatological tolerance 7
5.2.3. Cosmetic acceptability 7
6. CONCLUSION 8
APPENDICES 9

AUTHENTICITY OF THE RESULTS

The study giving rise to this report was conducted under my responsibility, in accordance with the experimental protocol and in the spirit of Good Clinical Practice. I certify that this report precisely reflects the study conducted as well as the results obtained.

Caterina PAHOMI, investigator
Dermatologist

Signature / date:

Digitally signed by Caterina PAHOMI
DN: cn=Caterina PAHOMI, o=C.T.I, ou=C.T.I, email=cti.idea@gmail.com, c=RO
Date: 2019.11.14 11:22:21 +02'00'
Adobe Acrobat version: 2019.021.20056

The generated data were checked by CTI's Quality Assurance in accordance with the current procedures. This report was audited by IDEA Clinic's Quality Assurance. It accurately reflects the raw data of the study.

Signature / date:

Lesly BOLTS
Clinical Quality Manager
2019.11.14 13:32:52 +01'00'
Emis par : CN=ChamberSign France - AC 2 étoiles, OU=0002 433702479, O=ChamberSign France, C=FR

GROUPE IDEA TESTS
IDEA

1. PURPOSE OF THE STUDY

At the request of **REPOLAR PHARMACEUTICALS OY** company, we have assessed, under dermatological control, the anti-acneic potential, of the clinical and dermatological tolerance and acceptability of a cosmetic product :

ABICARE CREME
Code ID-19/06897

used under normal use conditions recommended by the sponsor, over a period of 28 days.

2. INVESTIGATIONAL PRODUCT

2.1. Characteristics

Name	:	ABICARE CREME
IDEA Tests code	:	ID-19/06897
Batch number	:	102020
Aspect	:	Liquid
Colour	:	Light, almost white
Product type	:	Medical device
Product class	:	-
Storage conditions	:	Room temperature (20°C ± 5°C)
Expiry date	:	31/10/2020
Packaging	:	Plastic tube
Number of received samples	:	149

2.2. Instructions for use during the study

Apply a thin layer of the product, twice a day to skin area which needs to be treated.

3. EXPECTED POPULATION BY PROTOCOL

3.1. Number of volunteers to be included

30 volunteers had to be included. Approximately 10% additional volunteers had to be recruited in order to obtain the appropriate number of volunteers at the end of the study.

3.2. Inclusion criteria

Volunteers meeting the following criteria had to be included:
- healthy volunteer;
- volunteer between 18 and 45 years old;
- volunteer having a combination oily to oily skin on face with acne grade 1 to 2 on the GEA scale;
- normal clinical examination prior to inclusion;
- non-allergic and non-atopic;
- not exhibiting any dermatological lesion on the face;
- no past history of allergy to cosmetics or household products;
- volunteer who have signed a written free informed express consent;
- for the women: non post-menopausal, non-breast feeding and non-pregnant female;
- volunteer having signed a free clarified express written agreement giving their consent;
- volunteer able to understand the requirements of the study.

3.3. Non-inclusion criteria

Volunteers fulfilling the following criteria will not be included:
- volunteer with a general disease incompatible with the study;
- active dermatological disease or serious acne;
- volunteer having received treatment with Isotrétinoïne or an antiacneic oral contraceptive during the last six months;
- in receipt of anti-inflammatory drugs, corticosteroids, histamine antagonists, or any other treatment reducing or inhibiting inflammatory or allergic reactions; the prohibited medications are described in the current in-house manual;
- volunteer having received an antiacneic oral contraceptive during the last six months;
- woman who is pregnant, liable to become pregnant, or are breastfeeding;
- volunteer in the exclusion period between two studies.

3.4. Study imperatives

Each volunteer will be asked to do the following throughout the study period:
- attend all of the visits without having applied a hygiene, care and/or makeup product to the study site;
- not to handle face imperfections (papulae, comedones);
- not to intentionally or unintentionally expose themselves to UV light (natural or artificial);
- not to change his/her usual hygiene and cosmetic practices;
- not to use new cosmetic products;
- not to use another cosmetic product in the same class as the investigational product;
- not to undergo aesthetic or dermatological procedures;
- not to undergo a planned surgery;
- not to attend a beautician (for care, hair removal, “skin cleaning”, etc.).

4. METHODOLOGY

The study was monocentric, open and comparative between D28 and D1 (cf. specific protocol 233495).

4.1. Visit on D1 (V1)

- Inform the volunteer about the study process;
- Record signed, written, free, informed, express consent from the volunteer;
- Confirm that the inclusion and non-inclusion criteria are met;
- If the volunteer is eligible, allocate him/her an inclusion number in order of arrival into the study;
- Record the clinical examination (face), data from the counting of acne lesions and treatments currently being taken by the volunteer;
- Give the investigational product, the instructions for use and the logbook to the volunteer;
- Remind the volunteer about the restrictions required by the study, in particular the need to apply the last application a day before the next appointment and to attend the visits without having applied the product onto the face;
- Arrange a new appointment on D28 (V2) with the volunteer.

4.2. Visit on D28 (V2)

- Confirm that the protocol imperatives have been met;
- Confirm compliance of the applications;
- Recover the remaining product in its initial packaging;
- Record the volunteer's opinions about the cosmetic qualities of the product;
- Record the clinical examination, data from the counting of acne lesions and treatments possibly being taken by the volunteer during the study;
- Record the clinical signs and/or symptoms of the volunteer if necessary;

5. RESULTS AND ANALYSIS

5.1. Experimental conditions

Study site : CTI, Street Iuliu Teodori, Number (no.) 1, Sector 5, 050496 BUCHAREST, ROMANIA

Study dates
- Beginning : 16/09/2019
- End : 15/10/2019

5.1.1. Population analysed

Number of volunteers included : 32

Number of volunteers analysed : 31
- 22 women and 9 men
- average age of 36 years, between 23 and 45 years
- combination oily to oily skin on face with acne grade 1 to 2 on the GEA scale

5.1.2. Protocol deviation

Inclusion number	Type of deviation	Deviation description	Degree of deviation impact	Decision taken	Comments
1 and 16	Consumption of the product	Did not bring back their packaging at the end of the study	Minor	Partial impact on the study results	Not analyzed in the individual consumption calculation
27	Study appointment	Failed to appear on D28	Major	Withdrawal	« Lost to follow-up »

5.2. Results - discussion

5.2.1. Assessment of anti-acneic potential

	Total score		Comedones and microcysts		Papulae		Pustules		Nodules and cysts	
	D1	D28	D1	D28	D1	D28	D1	D28	D1	D28
Average	**11.5**	**8.5**	**8.5**	**7.0**	**3.1**	**1.5**	**0.0**	**0.0**	**0.0**	**0.0**
Standard deviation	5.0	3.8	2.1	2.1	3.6	2.5	0.0	0.0	0.0	0.0
Minimum	4	4	4	4	0	0	0	0	0	0
Maximum	23	18	13	12	10	10	0	0	0	0
The percentage of variation (%)	**-**	**-26.8**	**-**	**-17.6**	**-**	**-52.1**	**-**	-	**-**	-
p value Significance*	-	**p < 0.000 (S)**	-	**p < 0.000 (S)**	-	**p = 0.001 (S)**	-	-	-	-

*Wilcoxon test for paired data: S: Significant ($p \leq 0.05$) - NS: Non Significant ($p > 0.05$)

The analysis of data enabled to show a statistically significant decrease in the total score of acne lesions on D28 in comparison with D1 and particularly a statistically significant decrease in the number of comedones, microcysts and papulae.

5.2.2. Clinical and dermatological tolerance

No clinical sign of intolerance was observed.
No sensation of discomfort was reported.

5.2.3. Cosmetic acceptability

The volunteers evaluated the properties of the product after a 28-day period of application:
- Overall satisfaction: 87%
- Purchasing intention: 24 volunteers out of 31
- Items related to efficacy of the product (positive responses ≥ 70% *):
    - The product purifies the skin
    - The pores are uncloged

- The skin is visibly transformed
- The product helps to limit the formation of residual marks from pimples
- The product reduces residual marks from pimples
- The product eliminates skin imperfections
- The product reduces skin imperfections
- The product reduces the excess of sebum
- The product reduces pimples
- The product reduces blackheads
- The product tightens pores
- The product immediately matifies the skin
- The product matifies the skin
- The product is suitable for adults skin prone to acne
- The skin complexion is more radiant
- The product refines the skin texture
- The product is adapted to my skin type

** Statistical significant threshold for 31 analyzed volunteers*

6. CONCLUSION

Under the conditions of the study, the product:

ABICARE CREME
Code ID-19/06897

- **exhibited an anti acneic potential;**
- **exhibited an excellent dermatological tolerance, according to the adopted table, for** combination oily to oily skin on face**;**
- **and exhibited a good cosmetic acceptability, with 87% favourable opinions.**

APPENDICES

- Characteristics of the volunteers
- Individual and average consumption of the product
- Acne lesion scores
- Clinical examinations
- Cosmetic acceptability of the product and volunteer comments
- Study report abstracts (in French and English)
- Specific protocol 233495

Characteristics of the volunteers
ABICARE CREME

Inclusion no.	Initials	Sex	Age (years)	Type of facial skin	Volunteers self-declaring sensitive facial skin	Volunteers with an acne grade 1 to 2 on the GEA scale	Current treatments
1	PL-FL	M	31	Mixed oily	Yes	Yes	-
2	TO-DE	F	29	Mixed oily	No	Yes	-
3	PA-FL	M	45	Mixed oily	No	Yes	-
4	DE-BO	M	31	Mixed oily	Yes	Yes	-
5	DE-TU	M	33	Mixed oily	Yes	Yes	-
6	IA-CR	F	44	Mixed oily	Yes	Yes	-
7	PI-SO	M	33	Oily	Yes	Yes	-
8	DI-MI	F	24	Oily	Yes	Yes	-
9	MI-MI	F	38	Mixed oily	Yes	Yes	-
10	ST-AN	M	36	Mixed oily	No	Yes	-
11	TU-LA	F	27	Mixed oily	Yes	Yes	-
12	CH-CI	M	41	Oily	Yes	Yes	-
13	PA-AN	F	39	Mixed oily	Yes	Yes	-
14	MI-IO	F	39	Mixed oily	Yes	Yes	-
15	ST-IU	M	29	Oily	Yes	Yes	-
16	FE-AN	F	30	Oily	Yes	Yes	-
17	RO-PE	F	45	Mixed oily	No	Yes	-
18	RO-AN	F	37	Oily	Yes	Yes	-
19	VA-MI	F	44	Mixed oily	Yes	Yes	-
20	ST-MA	F	23	Mixed oily	Yes	Yes	-
21	RA-ST	F	37	Mixed oily	No	Yes	-
22	PU-EC	F	39	Oily	Yes	Yes	-
23	OA-VI	F	41	Oily	Yes	Yes	-
24	VI-CA	F	38	Mixed oily	No	Yes	-
25	ST-CO	F	41	Oily	Yes	Yes	-
26	ST-MI	F	41	Oily	Yes	Yes	-
27	ST-NI	F	32	Oily	No	Yes	-
28	CO-CR	F	29	Oily	Yes	Yes	-
29	TU-AD	F	41	Mixed oily	No	Yes	-
30	RO-MI	M	30	Mixed oily	Yes	Yes	-
31	NI-GE	F	26	Oily	Yes	Yes	-
32	CR-LA	F	45	Mixed oily	Yes	Yes	-

Individual and average consumption of the product
ABICARE CREME

Inclusion No.	Used amount (grams)	Number of applications	Individual consumption (grams)
1	The final consumption could not be calculated		
2	61.55	56	1.10
3	38.57	56	0.69
4	39.96	56	0.71
5	37.61	56	0.67
6	35.95	56	0.64
7	43.13	56	0.77
8	31.89	56	0.57
9	24.89	56	0.44
10	28.84	56	0.52
11	28.07	56	0.50
12	32.66	56	0.58
13	33.85	56	0.60
14	36.81	56	0.66
15	53.83	56	0.96
16	The final consumption could not be calculated		
17	49.15	56	0.88
18	36.46	56	0.65
19	35.32	56	0.63
20	52.95	56	0.95
21	36.80	56	0.66
22	32.95	56	0.59
23	47.77	56	0.85
24	25.48	56	0.46
25	33.57	56	0.60
26	44.34	56	0.79
27	Withdrawal		
28	43.25	56	0.77
29	42.70	56	0.76
30	59.60	56	1.06
31	58.47	56	1.04
32	27.77	56	0.50
Average	**39.80**	**56.00**	**0.71**

Acne lesion scores
ABICARE CREME

Inclusion no.	Total score		Comedones and microcysts		Papulae		Pustules		Nodules and cysts	
	D1	D28	D1	D28	D1	D28	D1	D28	D1	D28
1	15	7	9	7	6	0	0	0	0	0
2	10	5	6	5	4	0	0	0	0	0
3	12	6	8	6	4	0	0	0	0	0
4	16	18	8	8	8	10	0	0	0	0
5	16	10	8	6	8	4	0	0	0	0
6	9	7	9	7	0	0	0	0	0	0
7	17	12	9	8	8	4	0	0	0	0
8	18	11	12	9	6	2	0	0	0	0
9	6	4	6	4	0	0	0	0	0	0
10	8	5	8	5	0	0	0	0	0	0
11	13	9	9	7	4	2	0	0	0	0
12	6	5	6	5	0	0	0	0	0	0
13	20	11	10	7	10	4	0	0	0	0
14	5	4	5	4	0	0	0	0	0	0
15	16	10	8	6	8	4	0	0	0	0
16	7	5	7	5	0	0	0	0	0	0
17	10	7	10	7	0	0	0	0	0	0
18	14	10	10	8	4	2	0	0	0	0
19	8	6	8	6	0	0	0	0	0	0
20	18	16	10	10	8	6	0	0	0	0
21	14	11	12	11	2	0	0	0	0	0
22	16	10	10	8	6	2	0	0	0	0
23	8	6	8	6	0	0	0	0	0	0
24	11	10	11	10	0	0	0	0	0	0
25	23	18	13	12	10	6	0	0	0	0
26	7	6	7	6	0	0	0	0	0	0
27	Withdrawal									
28	7	6	7	6	0	0	0	0	0	0
29	4	4	4	4	0	0	0	0	0	0
30	5	5	5	5	0	0	0	0	0	0
31	10	9	10	9	0	0	0	0	0	0
32	9	9	9	9	0	0	0	0	0	0
Average	**11.5**	**8.5**	**8.5**	**7.0**	**3.1**	**1.5**	**0.0**	**0.0**	**0.0**	**0.0**
Standard deviation	5.0	3.8	2.1	2.1	3.6	2.5	0.0	0.0	0.0	0.0

Clinical examinations
ABICARE CREME

Inclusion no.	Initials		
1	PL-FL	**D1**- 16/09/19	Papules 1 / Cheeks - Chin Erythrosis and couperosis 1 / Cheeks Shininess 1 / Face
		D28- 14/10/19	Erythrosis and couperosis 1 / Cheeks Shininess 0.5 / Face
Inclusion no.	Initials		
2	TO-DE	**D1**- 16/09/19	Papules 1 / Cheeks Shininess 1 / T zone
		D28- 14/10/19	Shininess 0.5 / T zone
Inclusion no.	Initials		
3	PA-FL	**D1**- 16/09/19	Papules 1 / Cheeks Shininess 2 / T zone Shininess 1 / Cheeks
		D28- 14/10/19	Shininess 1 / Face
Inclusion no.	Initials		
4	DE-BO	**D1**- 16/09/19	Papules 1 / Forehead - Chin Shininess 1 / T zone
		D28- 14/10/19	Papules 1 / Forehead - Chin Shininess 1 / T zone
Inclusion no.	Initials		
5	DE-TU	**D1**- 16/09/19	Papules 1 / Cheeks Erythrosis and couperosis 1 / Cheeks Shininess 1 / T zone
		D28- 14/10/19	Papules 1 / Cheeks Erythrosis and couperosis 1 / Cheeks Shininess 1 / T zone
Inclusion no.	Initials		
6	IA-CR	**D1**- 16/09/19	Erythrosis and couperosis 1 / Cheeks Shininess 1 / Face
		D28- 14/10/19	Erythrosis and couperosis 1 / Cheeks Shininess 1 / T zone

Clinical examinations (continued)
ABICARE CREME

Inclusion no.	Initials		
7	PI-SO	**D1**- 16/09/19	Papules 1 / Cheeks - Chin Erythrosis and couperosis 1 / Cheeks - Chin Shininess 1 / Face
		D28- 14/10/19	Papules 1 / Chin Erythrosis and couperosis 1 / Cheeks - Chin Shininess 1 / Face
Inclusion no.	Initials		
8	DI-MI	**D1**- 16/09/19	Papules 1 / Cheeks - Chin Shininess 1 / Face
		D28- 14/10/19	Shininess 0.5 / T zone
Inclusion no.	Initials		
9	MI-MI	**D1**- 16/09/19	Shininess 1 / T zone
		D28- 14/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
10	ST-AN	**D1**- 16/09/19	Shininess 2 / T zone
		D28- 14/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
11	TU-LA	**D1**- 16/09/19	Papules 1 / Chin Shininess 2 / T zone Shininess 1 / Cheeks
		D28- 14/10/19	Papules 1 / Chin Shininess 2 / T zone
Inclusion no.	Initials		
12	CH-CI	**D1**- 16/09/19	Shininess 1 / Face
		D28- 14/10/19	Shininess 0.5 / T zone
Inclusion no.	Initials		
13	PA-AN	**D1**- 16/09/19	Papules 1 / Cheeks - Chin Shininess 1 / T zone
		D28- 14/10/19	Papules 1 / Chin Shininess 0.5 / T zone
Inclusion no.	Initials		
14	MI-IO	**D1**- 16/09/19	Shininess 1 / Face
		D28- 14/10/19	Shininess 1 / Face

Clinical examinations (continued)
ABICARE CREME

Inclusion no.	Initials		
15	ST-IU	**D1**- 16/09/19	Papules 1 / Chin Shininess 1 / Face
		D28- 14/10/19	Papules 1 / Chin Shininess 1 / T zone
Inclusion no.	Initials		
16	FE-AN	**D1**- 16/09/19	Shininess 2 / T zone Shininess 1 / Cheeks
		D28- 14/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
17	RO-PE	**D1**- 17/09/19	Shininess 2 / T zone Shininess 1 / Cheeks
		D28- 15/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
18	RO-AN	**D1**- 17/09/19	Papules 1 / Chin Shininess 2 / Face
		D28- 15/10/19	Papules 1 / Chin Shininess 2 / T zone Shininess 1 / Cheeks
Inclusion no.	Initials		
19	VA-MI	**D1**- 17/09/19	Shininess 1 / Face
		D28- 15/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
20	ST-MA	**D1**- 17/09/19	Papules 1 / Cheeks - Chin Erythrosis and couperosis 1 / Cheeks - Chin Shininess 1 / Face
		D28- 15/10/19	Papules 1 / Cheeks - Chin Erythrosis and couperosis 1 / Cheeks - Chin Shininess 1 / Face
Inclusion no.	Initials		
21	RA-ST	**D1**- 17/09/19	Papules 1 / Left cheek Shininess 2 / T zone Shininess 1 / Cheeks
		D28- 15/10/19	Shininess 2 / T zone

Clinical examinations (continued)
ABICARE CREME

Inclusion no.	Initials		
22	PU-EC	**D1**- 17/09/19	Papules 1 / Cheeks - Forehead Shininess 2 / Face
		D28- 15/10/19	Papules 1 / Left cheek Shininess 1 / Face
Inclusion no.	Initials		
23	OA-VI	**D1**- 17/09/19	Shininess 2 / T zone Shininess 1 / Cheeks
		D28- 15/10/19	Shininess 1 / Face
Inclusion no.	Initials		
24	VI-CA	**D1**- 17/09/19	Shininess 2 / T zone
		D28- 15/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
25	ST-CO	**D1**- 17/09/19	Papules 1 / Cheeks - Forehead - Chin Shininess 2 / Face
		D28- 15/10/19	Papules 1 / Cheeks - Forehead Shininess 2 / T zone Shininess 1 / Cheeks
Inclusion no.	Initials		
26	ST-MI	**D1**- 17/09/19	Erythrosis and couperosis 1 / Cheeks Shininess 1 / Face
		D28- 15/10/19	Erythrosis and couperosis 1 / Cheeks Shininess 1 / Face
Inclusion no.	Initials		
27	ST-NI	**D1**- 17/09/19	Papules 1 / Cheeks - Chin Shininess 2 / Face
		D28- 15/10/19	Withdrawal
Inclusion no.	Initials		
28	CO-CR	**D1**- 17/09/19	Erythrosis and couperosis 1 / Cheeks Shininess 1 / Face
		D28- 15/10/19	Erythrosis and couperosis 1 / Cheeks Shininess 0.5 / Face

Clinical examinations (continued)
ABICARE CREME

Inclusion no.	Initials		
		D1- 17/09/19	Shininess 1 / T zone
29	TU-AD	**D28**- 15/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
		D1- 17/09/19	Shininess 1 / T zone
30	RO-MI	**D28**- 15/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
		D1- 17/09/19	Shininess 1 / Face
31	NI-GE	**D28**- 15/10/19	Shininess 1 / T zone
Inclusion no.	Initials		
		D1- 17/09/19	Shininess 2 / T zone
32	CR-LA	**D28**- 15/10/19	Shininess 1 / T zone

Rating: 0.5: very slight; 1: slight; 2: moderate; 3: severe

Cosmetic acceptability of the product and volunteer comments
ABICARE CREME

FILE 52177 - ABICARE CREME

Q1 Please note your inclusion number which is between 0 and 99 written on your study information sheet (sheet where are the instructions for use).

Answered: 31 Skipped: 0

#	RESPONSES	DATE
1	02	10/18/2019 1:00 PM
2	13	10/18/2019 12:59 PM
3	01	10/18/2019 12:58 PM
4	08	10/18/2019 12:57 PM
5	19	10/18/2019 12:56 PM
6	07	10/18/2019 12:55 PM
7	12	10/18/2019 12:55 PM
8	17	10/18/2019 12:54 PM
9	32	10/18/2019 12:50 PM
10	30	10/18/2019 12:49 PM
11	31	10/18/2019 12:49 PM
12	29	10/18/2019 12:48 PM
13	28	10/18/2019 12:48 PM
14	26	10/18/2019 12:47 PM
15	25	10/18/2019 12:47 PM
16	24	10/18/2019 12:46 PM
17	23	10/18/2019 12:45 PM
18	22	10/18/2019 12:45 PM
19	20	10/18/2019 12:44 PM
20	21	10/18/2019 12:44 PM
21	18	10/18/2019 12:43 PM
22	16	10/16/2019 1:21 PM
23	14	10/14/2019 4:48 PM
24	05	10/14/2019 4:26 PM
25	11	10/14/2019 3:43 PM
26	09	10/14/2019 3:30 PM
27	04	10/14/2019 3:28 PM
28	15	10/14/2019 3:10 PM
29	06	10/14/2019 3:08 PM
30	10	10/14/2019 1:38 PM
31	03	10/14/2019 1:10 PM

Q2 Did you apply the product twice a day?

Answered: 31 Skipped: 0

ANSWER CHOICES	RESPONSES	
YES	100.00%	31
If NO, why ?	0.00%	0
TOTAL		31

#	IF NO, WHY ?	DATE
	There are no responses.	

Q3 Please indicate the date of the last application of the product :

Answered: 31 Skipped: 0

ANSWER CHOICES	RESPONSES	
Date	100.00%	31

#	DATE	DATE
1	13/10/2019	10/18/2019 1:00 PM
2	13/10/2019	10/18/2019 12:59 PM
3	13/10/2019	10/18/2019 12:58 PM
4	13/10/2019	10/18/2019 12:57 PM
5	14/10/2019	10/18/2019 12:56 PM
6	13/10/2019	10/18/2019 12:55 PM
7	13/10/2019	10/18/2019 12:55 PM
8	14/10/2019	10/18/2019 12:54 PM
9	14/10/2019	10/18/2019 12:50 PM
10	14/10/2019	10/18/2019 12:49 PM
11	14/10/2019	10/18/2019 12:49 PM
12	14/10/2019	10/18/2019 12:48 PM
13	14/10/2019	10/18/2019 12:48 PM
14	14/10/2019	10/18/2019 12:47 PM
15	14/10/2019	10/18/2019 12:47 PM
16	14/10/2019	10/18/2019 12:46 PM
17	14/10/2019	10/18/2019 12:45 PM
18	14/10/2019	10/18/2019 12:45 PM
19	14/10/2019	10/18/2019 12:44 PM
20	14/10/2019	10/18/2019 12:44 PM
21	14/10/2019	10/18/2019 12:43 PM
22	13/10/2019	10/16/2019 1:21 PM
23	13/10/2019	10/14/2019 4:48 PM
24	13/10/2019	10/14/2019 4:26 PM
25	13/10/2019	10/14/2019 3:43 PM
26	13/10/2019	10/14/2019 3:30 PM
27	13/10/2019	10/14/2019 3:28 PM
28	13/10/2019	10/14/2019 3:10 PM
29	13/10/2019	10/14/2019 3:08 PM
30	13/10/2019	10/14/2019 1:38 PM
31	13/10/2019	10/14/2019 1:10 PM

Q4 Please indicate the time of the last application of the product: (FORMAT = HH:0-12 / MM:0-59) Application before noon,tick AM Application after noon, tick PM

Answered: 31 Skipped: 0

ANSWER CHOICES	RESPONSES	
Time	100.00%	31

#	TIME	DATE
1	05:30 PM	10/18/2019 1:00 PM
2	06:30 PM	10/18/2019 12:59 PM
3	09:15 PM	10/18/2019 12:58 PM
4	07:55 PM	10/18/2019 12:57 PM
5	08:45 PM	10/18/2019 12:56 PM
6	08:10 PM	10/18/2019 12:55 PM
7	09:20 PM	10/18/2019 12:55 PM
8	04:30 PM	10/18/2019 12:54 PM
9	09:00 PM	10/18/2019 12:50 PM
10	09:00 PM	10/18/2019 12:49 PM
11	10:00 PM	10/18/2019 12:49 PM
12	06:00 PM	10/18/2019 12:48 PM
13	04:00 PM	10/18/2019 12:48 PM
14	09:30 PM	10/18/2019 12:47 PM
15	09:00 PM	10/18/2019 12:47 PM
16	07:30 PM	10/18/2019 12:46 PM
17	08:45 PM	10/18/2019 12:45 PM
18	06:00 PM	10/18/2019 12:45 PM
19	08:00 PM	10/18/2019 12:44 PM
20	08:00 PM	10/18/2019 12:44 PM
21	09:00 PM	10/18/2019 12:43 PM
22	09:00 PM	10/16/2019 1:21 PM
23	09:00 PM	10/14/2019 4:48 PM
24	09:00 PM	10/14/2019 4:26 PM
25	07:00 PM	10/14/2019 3:43 PM
26	07:00 PM	10/14/2019 3:30 PM
27	07:00 PM	10/14/2019 3:28 PM
28	07:00 PM	10/14/2019 3:10 PM
29	09:00 PM	10/14/2019 3:08 PM
30	09:00 PM	10/14/2019 1:38 PM
31	09:00 PM	10/14/2019 1:10 PM

Q5 Please tick the appropriate box:

Answered: 31 Skipped: 0

	COMPLETELY AGREE	AGREE	SLIGHTLY DISAGREE	DISAGREE	TOTAL	WEIGHTED AVERAGE
The product is easy to apply	16.13% 5	83.87% 26	0.00% 0	0.00% 0	31	100.00
The product is easily absorbed	19.35% 6	70.97% 22	6.45% 2	3.23% 1	31	90.32
The product is not greasy and sticky	12.90% 4	70.97% 22	16.13% 5	0.00% 0	31	83.87
The product purifies the skin	45.16% 14	54.84% 17	0.00% 0	0.00% 0	31	100.00
The pores are uncloged	9.68% 3	87.10% 27	3.23% 1	0.00% 0	31	96.77
The skin is visibly transformed	9.68% 3	77.42% 24	12.90% 4	0.00% 0	31	87.10
The product helps to limit the formation of residual marks from pimples	9.68% 3	80.65% 25	9.68% 3	0.00% 0	31	90.32
The product reduces residual marks from pimples	12.90% 4	77.42% 24	9.68% 3	0.00% 0	31	90.32
The product eliminates skin imperfections	12.90% 4	67.74% 21	19.35% 6	0.00% 0	31	80.65
The product reduces skin imperfections	22.58% 7	67.74% 21	9.68% 3	0.00% 0	31	90.32
The product reduces the excess of sebum	16.13% 5	74.19% 23	9.68% 3	0.00% 0	31	90.32
The product reduces pimples	19.35% 6	70.97% 22	9.68% 3	0.00% 0	31	90.32
The product reduces blackheads	16.13% 5	70.97% 22	12.90% 4	0.00% 0	31	87.10
The product tightens pores	9.68% 3	80.65% 25	9.68% 3	0.00% 0	31	90.32
The product immediately matifies the skin	12.90% 4	64.52% 20	22.58% 7	0.00% 0	31	77.42
The product matifies the skin	12.90% 4	77.42% 24	9.68% 3	0.00% 0	31	90.32
The product is suitable for adults skin prone to acne	6.45% 2	83.87% 26	9.68% 3	0.00% 0	31	90.32
The skin complexion is more radiant	0.00% 0	90.32% 28	9.68% 3	0.00% 0	31	90.32
The product refines the skin texture	3.23% 1	83.87% 26	12.90% 4	0.00% 0	31	87.10
The product is adapted to my skin type	9.68% 3	80.65% 25	9.68% 3	0.00% 0	31	90.32
Your impression of the product is good	9.68% 3	77.42% 24	12.90% 4	0.00% 0	31	87.10

Q6 What did you especially like about this product?

Answered: 31 Skipped: 0

#	RESPONSES	DATE
1	The product is easily absorbed, the product is not greasy and sticky	10/18/2019 1:00 PM
2	The product reduces pimples	10/18/2019 12:59 PM
3	The product purifies the skin	10/18/2019 12:58 PM
4	The texture, the product reduces pimples	10/18/2019 12:57 PM
5	The product reduces skin imperfections	10/18/2019 12:56 PM
6	The product is easy to apply	10/18/2019 12:55 PM
7	The product is easy to apply	10/18/2019 12:55 PM
8	The texture	10/18/2019 12:54 PM
9	The product reduces skin imperfections	10/18/2019 12:50 PM
10	The product is easily absorbed	10/18/2019 12:49 PM
11	The product purifies the skin, the odour	10/18/2019 12:49 PM
12	The product is easily absorbed	10/18/2019 12:48 PM
13	The product purifies the skin	10/18/2019 12:48 PM
14	The product matifies the skin	10/18/2019 12:47 PM
15	The product is not greasy	10/18/2019 12:47 PM
16	The skin is clean	10/18/2019 12:46 PM
17	Everything	10/18/2019 12:45 PM
18	The product reduces blackheads	10/18/2019 12:45 PM
19	The product purifies the skin	10/18/2019 12:44 PM
20	The product eliminates skin imperfections	10/18/2019 12:44 PM
21	The product purifies the skin	10/18/2019 12:43 PM
22	The skin complexion is more radiant	10/16/2019 1:21 PM
23	The product reduces skin imperfections	10/14/2019 4:48 PM
24	The product reduces skin imperfections	10/14/2019 4:26 PM
25	The texture, the product is easily abosrbed	10/14/2019 3:43 PM
26	The product is easily absorbed	10/14/2019 3:30 PM
27	The product is easy to apply	10/14/2019 3:28 PM
28	The product is easily absorbed	10/14/2019 3:10 PM
29	The product is easily absorbed	10/14/2019 3:08 PM
30	The product reduces pimples	10/14/2019 1:38 PM
31	Everything	10/14/2019 1:10 PM

Q7 What did you especially dislike about this product?

Answered: 31 Skipped: 0

#	RESPONSES	DATE
1	Nothing	10/18/2019 1:00 PM
2	Nothing	10/18/2019 12:59 PM
3	Nothing	10/18/2019 12:58 PM
4	Nothing	10/18/2019 12:57 PM
5	Nothing	10/18/2019 12:56 PM
6	The product does not reduce imperfections	10/18/2019 12:55 PM
7	The odour	10/18/2019 12:55 PM
8	The lack of fragrance	10/18/2019 12:54 PM
9	Nothing	10/18/2019 12:50 PM
10	Nothing	10/18/2019 12:49 PM
11	Nothing	10/18/2019 12:49 PM
12	The product does not reduce imperfections	10/18/2019 12:48 PM
13	Nothing	10/18/2019 12:48 PM
14	Nothing	10/18/2019 12:47 PM
15	Nothing	10/18/2019 12:47 PM
16	Nothing	10/18/2019 12:46 PM
17	Nothing	10/18/2019 12:45 PM
18	Nothing	10/18/2019 12:45 PM
19	Nothing	10/18/2019 12:44 PM
20	Nothing	10/18/2019 12:44 PM
21	The product is not easily absorbed	10/18/2019 12:43 PM
22	Nothing	10/16/2019 1:21 PM
23	Nothing	10/14/2019 4:48 PM
24	The odour, the sticky texture	10/14/2019 4:26 PM
25	Nothing	10/14/2019 3:43 PM
26	The odour	10/14/2019 3:30 PM
27	The product is not suitable for adults skin prone to acne	10/14/2019 3:28 PM
28	The odour	10/14/2019 3:10 PM
29	The odour	10/14/2019 3:08 PM
30	The odour	10/14/2019 1:38 PM
31	Nothing	10/14/2019 1:10 PM

Q8 Would you buy this product?

Answered: 31 Skipped: 0

ANSWER CHOICES	RESPONSES	
Yes	77.42%	24
No	22.58%	7
TOTAL		31

RESUME DU RAPPORT D'ETUDE

Promoteur	Moniteur	Lieu de réalisation
REPOLAR PHARMACEUTICALS OY, Suomalaistentie 7, 02270 ESPOO FINLAND	IDEA Clinic Technopole Montesquieu, 5 rue Jacques Monod, CS 60077 33652 MARTILLAC CEDEX FRANCE	CTI Street Iuliu Teodori, Number (no.) 1, Sector 5, 050496 BUCHAREST, ROMANIA

Investigateur : Caterina PAHOMI, Dermatologue
Références internes : 52177 - 2.21_28J - ID-19/06897

DESCRIPTION DE L'ETUDE

Evaluation du potentiel anti-acnéique, de la tolérance clinique et dermatologique et de l'acceptabilité d'un produit cosmétique après utilisation sur une période de 28 jours dans les conditions normales d'emploi – test sous contrôle dermatologique

Produit étudié : ABICARE CREME

Mode d'emploi retenu pour l'étude : deux fois par jour, appliquer le produit en couche mince sur les zones de la peau à traiter.

Site examiné : visage

Critères d'évaluation :
- Evaluation du potentiel non comédogène : dénombrement des lésions acnéiques à J1 et J28
- Evaluation de la tolérance clinique et dermatologique : examen clinique à J1 et J28 ; remontée des sensations d'inconfort par le volontaire.
- Evaluation de l'acceptabilité cosmétique : questionnaire complété par le volontaire à J28.

RESULTATS - DISCUSSION

Dates de l'étude : du 16/09/2019 au 15/10/2019

Population analysée :
Nombre de volontaires inclus : 32
Nombre de volontaires analysés : 31 (1 abandon : le volontaire n°27)
- 22 femmes et 9 hommes
- âge moyen de 36 ans, compris entre 23 et 45 ans
- peau grasse à mixte grasse au niveau du visage ayant une acné de grade 1 à 2 sur l'échelle GEA

Evaluation du potentiel anti-acnéique :

	Score total		Comédons et microkystes		Papules		Pustules		Nodules et kystes	
	J1	**J28**	**J1**	**J28**	**J1**	**J28**	**J1**	**J28**	**J1**	**J28**
Moyenne	**11,5**	**8,5**	**8,5**	**7,0**	**3,1**	**1,5**	**0,0**	**0,0**	**0,0**	**0,0**
Ecart type	5,0	3,8	2,1	2,1	3,6	2,5	0,0	0,0	0,0	0,0
Minimum	4	4	4	4	0	0	0	0	0	0
Maximum	23	18	13	12	10	10	0	0	0	0
Pourcentage de variation (%)	**-**	**-26,8**	**-**	**-17,6**	**-**	**-52,1**	**-**	**-**	**-**	**-**
Valeur de p Significativité*	-	**p < 0,000 (S)**	-	**p < 0,000 (S)**	-	**p = 0,001 (S)**	-	**-**	-	**-**

*Test de Wilcoxon pour données appariées : S: Significatif (p ≤ 0.05) - NS : Non Significatif (p > 0.05)

L'analyse des donnés a permis de mettre en évidence une diminution statistiquement significative du score total de lésions acnéiques à J28 par rapport à J1 avec en particulier une diminution statistiquement significative du nombre de comédons, de microkystes et de papules.

Tolérance clinique et dermatologique :

- aucun signe clinique d'intolérance n'a été observé.
- aucune sensation d'inconfort n'a été rapportée.

CONCLUSION

Dans les conditions de l'étude, le produit :

- **a présenté un potentiel anti-acnéique ;**
- **a présenté une excellente tolérance dermatologique, d'après le barème adopté, sur la peau grasse à mixte grasse du visage ;**
- **et a présenté une bonne acceptabilité cosmétique, avec 87 % d'opinions favorables.**

STUDY REPORT ABSTRACT

Sponsor	Monitor	Place of study
REPOLAR PHARMACEUTICALS OY Suomalaistentie 7, 02270 ESPOO FINLAND	IDEA CLINIC Technopole Montesquieu, 5, rue Jacques Monod, CS 60077, 33652 MARTILLAC CEDEX FRANCE	CTI Street Iuliu Teodori, Number (no.) 1, Sector 5, 050496 BUCHAREST, ROMANIA

Investigator : Caterina PAHOMI, Dermatologist
Internal references : 52177 - 2.21_28J - ID-19/06897

DESCRIPTION OF THE STUDY

Assessment of anti-acneic potential, of the clinical and the dermatological tolerance and acceptability of a cosmetic product after a 28-day period of application under normal conditions of use – in use test under dermatological control.

Investigational product: ABICARE CREME

Instructions for use during the study: apply a thin layer of the product, twice a day to skin area which needs to be treated.

Examined site: face

Assessment criteria:
- Assessment of anti-acneic potential: counting of the number of acne lesions on D1 and D28
- Assessment of clinical and dermatological tolerance: clinical examination on D1 and D28; report of feelings of discomfort by the volunteer.
- Assessment of cosmetic acceptability: questionnaire completed by the volunteer on D1 and D28.

RESULTS - DISCUSSION

Dates of study: from 16/09/2019 to 15/10/2019

Population analysed:
Number of volunteers included : 32
Number of volunteers analysed : 31 (1 withdrawal: volunteer no.27)
- 22 women and 9 men
- average age of 36 years, between 23 and 45 years
- combination oily to oily skin on face with acne grade 1 to 2 on the GEA scale

Assessment of anti-acneic potential:

	Total score		Comedones and microcysts		Papulae		Pustules		Nodules and cysts	
	D1	**D28**	**D1**	**D28**	**D1**	**D28**	**D1**	**D28**	**D1**	**D28**
Average	**11.5**	**8.5**	**8.5**	**7.0**	**3.1**	**1.5**	**0.0**	**0.0**	**0.0**	**0.0**
Standard deviation	5.0	3.8	2.1	2.1	3.6	2.5	0.0	0.0	0.0	0.0
Minimum	4	4	4	4	0	0	0	0	0	0
Maximum	23	18	13	12	10	10	0	0	0	0
The percentage of variation (%)	**-**	**-26.8**	**-**	**-17.6**	**-**	**-52.1**	**-**	-	**-**	-
p value Significance*	-	**p < 0.000 (S)**	-	**p < 0.000 (S)**	-	**p = 0.001 (S)**	-	-	-	-

*Wilcoxon test for paired data: S: Significant ($p \leq 0.05$) - NS: Non Significant ($p > 0.05$)

The analysis of data enabled to show a statistically significant decrease in the total score of acne lesions on D28 in comparison with D1 and particularly a statistically significant decrease in the number of comedones, microcysts and papulae.

Clinical and dermatological tolerance:
- no clinical sign of intolerance was observed.
- no feeling of discomfort was reported.

CONCLUSION

Under the conditions of the study, the product exhibited:
- **an anti acneic potential;**
- **an excellent dermatological tolerance, according to the adopted table, for** combination oily to oily skin on face;
- **and a good cosmetic acceptability, with 87% favourable opinions.**

Specific protocol study n°233 495

Assessment of anti-acneic potential, of the clinical and dermatological tolerance and acceptability of a cosmetic product after a 28-day period of application under normal conditions of use – in use test under dermatological control on 30 volunteers

Protocol version:	**1**
Investigator:	**Caterina PAHOMI,**
Protocol date:	**27 June 2019**

REPOLAR PHARMACEUTICALS OY **Suomalaistentie 7** **02270 ESPOO** **FINLAND**	**Study Centre** **IDEA Clinic** **Montesquieu Site - CS 60077** **5 rue Jacques Monod** **33652 MARTILLAC** **FRANCE**

TABLE OF CONTENTS

1. PURPOSE OF THE STUDY 4
2. PRODUCT 4
2.1. Investigational product 4
2.2. Responsibility of the sponsor 5
2.3. Management 5
3. STUDY POPULATION 5
3.1. General characteristics 5
3.2. Inclusion criteria 6
3.3. Non-inclusion criteria 6
3.4. Study imperatives 7
3.5. Exclusion criteria 7
4. METHODOLOGY 7
4.1. Study process 7
4.2. Assessment criteria 8
4.3. Analysis of results 9
4.4. Adverse events 11
4.5. Management in the event of exclusion 12
4.6. Management in the event of protocol deviation 13
4.7. Protocol amendment 13
5. LEGAL FRAMEWORK, ETHICAL AND LEGAL CONSIDERATIONS 13
5.1. Regulations 13
5.2. Confidentiality 14
5.3. Insurance taken out by IDEA Clinic 14
5.4. Quality management 14
5.5. ARCHIVING 15
6. SIGNATURE 15

GLOSSARY

The following terms and definitions apply for the purposes of this document:

Adverse effect: a harmful, undesired reaction occurring under normal conditions of use of the product in human beings or following misuse.

Adverse event: any harmful reaction occurring in a person taking part in the biomedical research whether or not this reaction is due to the research or to the product of which the research is being carried out.

Clinical sign: an adverse effect noted by the evaluator and/or the volunteer during the product use.

Exclusion from the study: exclusion of the volunteer on the decision of the investigator.

Exclusion: early discontinuation of the participation of a volunteer in the clinical study either by the person concerned or by the investigator.

Misuse: non-compliant use of the product with regard to its normal use, methods of use or specific precautions for use.

Protocol amendment: a change made deliberately to the protocol after the study start date.

Protocol deviation: a non-deliberate deviation from the protocol occurring after the study start date.

Serious adverse event: a reaction resulting in permanent or temporary functional incapacity, invalidity, hospitalisation; a reaction that is immediately life-threatening, or causes death or a congenital abnormality or malformation.

Symptom: an adverse effect experienced by the volunteer during use of the product (sensation of discomfort).

Volunteer: a healthy human being taking part voluntarily in a clinical study.

Withdrawal: a volunteer who is “lost to follow up” or withdraws his/her consent for a clinical study.

1. PURPOSE OF THE STUDY

To assess of the anti-acneic potential, of the clinical and dermatological tolerance and acceptability of a cosmetic product used under normal conditions for use as recommended by the sponsor for a 28-day period under dermatological control; and, generally speaking, to assess the ability of the product to keep the skin in good condition.

2. PRODUCT

2.1. Investigational product

2.1.1. Characteristics

Name	:	ABICARE CREME
IDEA TESTS code	:	ID-19/06897
Batch number	:	102020
Aspect	:	Liquid
Colour	:	Light, almost white
Product type	:	Medical device
Product class	:	-
Storage conditions	:	Room temperature (20°C ± 5°C)
Expiry date	:	31/10/2020

2.1.2. Instructions for use

Twice a day application, in thin layer, on clean and dry facial skin.

2.2. Responsibility of the sponsor

The sponsor will communicate the data about the investigational product and guarantees that these are accurate. The sponsor will also attest that the product is:
- formulated in compliance with Regulation (EC) No 1223/2009 of 30 November 2009 on cosmetics;
- manufactured according to Good Manufacturing Practice, guaranteeing physicochemical and microbiological quality which meets the manufacturer's specifications;
- formulated from ingredients with physicochemical and microbiological characteristics which comply with the manufacturer's specifications.

The data communicated must correspond in their entirety to the samples received.
The sponsor is the guarantor that the transport conditions for products sent to the IDEA Clinic are met.

2.3. Management

Each product received is controlled and identified with a unique code. Each product sample is (re)labelled in order to guarantee its traceability throughout the study.
The product samples will be stored at room temperature and may be exposed to light.
The remaining samples will be destroyed by a specialist company or may be returned to the sponsor at the sponsor's request.

3. STUDY POPULATION

3.1. General characteristics

3.1.1. Medical validation

Healthy subjects recruited from the IDEA Clinic general panel of volunteers or, where applicable, by its subcontractor. In order to be registered in the panel, each volunteer must undergo a medical validation by the recruiting centre doctor, provide evidence of social cover, and be an adult. From this panel, volunteers who meet the inclusion criteria are called up and then definitively included in the study at the end of the initial assessment.

3.1.2. Ethics and consent

Before being included, each volunteer is informed of:
- the purpose of the study;
- the constraints of the study and predictable risks, including those in the event of the study stopping prior to its term;
- the obligation to report any adverse event, any start of pregnancy, or any medication taken during the study;
- the length of the exclusion period, financial compensation sum, and the possibility to confirm the accuracy of data contained in the subject's clinical file and their subsequent archiving in sealed form;
- the possibility to stop the study at any time by informing the investigator.

This information is included in a written, free, informed, express consent form to participate in the study produced in duplicate and signed by the volunteer and the investigator. One copy will be stored by the volunteer and the other by the study centre.

3.1.3. Number of volunteers

30 volunteers will be included (approximately 10% additional volunteers will be recruited in order to obtain the appropriate number of volunteers at the end of the study).

3.2. Inclusion criteria

Volunteers who meet the following criteria may be included:
- healthy volunteer;
- volunteer between 18 and 45 years old;
- volunteer having an oily to mixte oily on facial skin with acne grade 1 to 2 on the GEA scale;
- normal clinical examination prior to inclusion;
- non-allergic and non-atopic;
- not exhibiting any dermatological lesion on the face;
- no past history of allergy to cosmetics or household products;
- volunteer who have signed a written free informed express consent;
- For the women: Non post-menopausal, non-breast feeding and non-pregnant female;
- volunteer having signed a free clarified express written agreement giving their consent;
- volunteer able to understand the requirements of the study.

3.3. Non-inclusion criteria

Volunteers fulfilling the following criteria will not be included:
- volunteer with a general disease incompatible with the study;
- active dermatological disease or serious acne;
- volunteer having received treatment with Isotrétinoïne or an antiacneic oral contraceptive during the last six months;
- in receipt of anti-inflammatory drugs, corticosteroids, histamine antagonists, or any other treatment reducing or inhibiting inflammatory or allergic reactions; the prohibited medications are described in the current in-house manual;
- volunteer having received an antiacneic oral contraceptive during the last six months;
- woman who is pregnant, liable to become pregnant, or are breastfeeding;
- volunteer in the exclusion period between two studies.

3.4. Study imperatives

Each volunteer will be asked to do the following throughout the study period:
- attend all of the visits without having applied a hygiene, care and/or makeup product to the study site;
- not to handle face imperfections (papulae, comedones);
- not to intentionally or unintentionally expose themselves to UV light (natural or artificial);
- not to change his/her usual hygiene and cosmetic practices;
- not to use new cosmetic products;
- not to use another cosmetic product in the same class as the investigational product;
- not to undergo aesthetic or dermatological procedures;
- not to undergo a planned surgery;
- not to attend a beautician (for care, hair removal, “skin cleaning”, etc.).

3.5. Exclusion criteria

After participating in the study, the volunteer should respect a 14-day exclusion period before participating in another study. In the case of adverse event, the period of exclusion will last for at least 30 days.

4. METHODOLOGY

The study is open, single centre and comparative between D28 and D1.

4.1. Study process

4.1.1. Visit on D1 (V1)

- Inform the volunteer about the study process;
- Record signed, written, free, informed, express consent from the volunteer;
- Confirm that the inclusion and non-inclusion criteria are met;
- If the volunteer is eligible, allocate him/her an inclusion number in order of arrival into the study;
- Record the clinical examination (face), data from the counting of acne lesions and treatments currently being taken by the volunteer;
- Give the investigational product, the instructions for use and the logbook to the volunteer;
- Remind the volunteer about the restrictions required by the study, in particular the need to apply the last application a day before the next appointment and to attend the visits without having applied the product onto the face;
- Arrange a new appointment on D28 (V2) with the volunteer.

4.1.2. Visit on D28 (V2)

- Confirm that the protocol imperatives have been met;
- Confirm compliance of the applications;
- Recover the remaining product in its initial packaging;
- Record the volunteer's opinions about the cosmetic qualities of the product;
- Record the clinical examination, data from the counting of acne lesions and treatments possibly being taken by the volunteer during the study;
- Record the clinical signs and/or symptoms of the volunteer if necessary;

4.1.3. Data collection

The data will be re-copied as the study is conducted and will be recorded following the applicable procedures.

4.1.4. End of study rules

The study will end when all the included volunteers have presented to the end of study visit (except for exclusions).

4.2. Assessment criteria

4.2.1. Anti-acneic potential

Different acne lesions (comedones/microcysts, papulae, pustules, nodules/cysts) will be counted on the whole face, except the nasal pyramid, on days D1 and D28 and each type of lesion will be weighted by a coefficient:

- total number of comedones/microcysts : multiplied by a factor of 1
- total number of papulae : multiplied by a factor of 2
- total number of pustules : multiplied by a factor of 3
- total number of nodules / cysts : multiplied by a factor of 4

4.2.2. Clinical and dermatological tolerance

In order to assess clinical and dermatological tolerance, a clinical examination on face will be carried out on each visit. The examinations will be performed by the same assessor (investigator or clinical assistant) under the supervision of the investigator throughout the study wherever possible.

Each criterion will be scored from 0 to 3 (0 = absent, 0.5 = very mild, 1 = mild, 2 = moderate, 3 = severe).

The examinations will be conducted under the appropriate temperature conditions.

4.2.2.1. Clinical and dermatological tolerance

The investigator will use the following criteria:
- erythema;
- oedema;
- roughness;
- dryness;
- desquamation;
- papules, pustules, vesicles, bullae;
- itching, tingling sensation, tautness;
- erythrosis and couperose;
- shininess;
- microcysts;
- others.

The assessor will complete a specific document should an adverse effect occur.

4.2.2.2. Report of feelings of discomfort by the volunteer

Should feelings of discomfort occur during the study, the assessor will complete a specific document with the volunteer which will, for example, include the following criteria:
- tautness;
- redness;
- tingling sensation;
- dryness;
- small spots;
- itching;
- watering;
- swelling.

4.2.3. Cosmetic acceptability

In order to assess the cosmetic acceptability, each volunteer will reported, in an individually questionnaire, their impressions on the cosmetic qualities of the investigational product.

4.3. Analysis of results

The volunteer's characteristics at inclusion and clinical findings will be presented using descriptive statistics.

4.3.1. Assessment of the anti-acneic potential

The sum of each total number of acne lesions type, after weighting, will be calculated for each volunteer at each experimental time and a total acne score will be get.
The assessment of efficacy of the product will be determined by statistical analysis (Software used: IBM SPSS 23).The statistics analysis will be performed by comparing the number of acne lesions on D28 vs D1 using the Wilcoxon test for paired data. The significant threshold will be set at $\alpha = 0.05$.

4.3.2. Overall assessment of clinical and dermatological tolerance

Overall tolerance	Clinical signs observed by the assessor		Sensations of discomfort reported by the volunteer
Excellent*	None	And	None
Very good**	None	And	Very mild or mild*** in intensity and short-lasting in a maximum of 10% of volunteers
Good	Very mild to moderate in intensity in a maximum of 10% of volunteers	And/or	Very mild to moderate in intensity in a maximum of 30% of volunteers
Average	Very mild to moderate in intensity in more than 10% to 20% of volunteers or severe in intensity in a maximum of 10% of volunteers	And/or	Very mild to moderate in intensity in 30% to 50% of volunteers or severe in intensity in a maximum of 30% of volunteers
Poor	Very mild to moderate in intensity in more than 20% of volunteers and severe in intensity in over 10% of volunteers	And/or	Very mild to moderate in intensity in 50% of volunteers or severe in intensity in over 30% of volunteers

* From 20 volunteers analysed
** From 15 volunteers analysed
*** Very mild or mild in intensity and short-lasting sensations are not included if they are only reported once by a single volunteer.

Note: the investigator reserves the right to amend her conclusion depending upon the class of product, or study population, etc.

4.3.3. Check consumption

In order to check the consumption of the product, each volunteer will be asked to do the following:
- to bring back his/her labelled sample (s) at the end of the study;
- to report in his/her acceptability questionnaire the compliance or non-compliance with the instructions for use: number of applications, date and time of the last application.

4.3.3.1. Number of applications

The number of applications is calculated in accordance with the instructions for use of the study.
The number of applications will be considered as non-compliant if it is higher or lower than the number of specified applications with a margin of -/+ 10%.

4.3.3.2. Consumption

The average consumption of each volunteer is calculated as follows:

$$Average\ consumption = \frac{(initial\ quantity - final\ quantity}{number\ of\ applications\ *}$$

* number of applications by the volunteer

A standard deviation will be calculated based on all the consumptions of the panel of volunteers.
The consumption of one volunteer will be considered as non-compliant if it is higher or lower than the average consumption, including the double standard deviation. Such non-compliance will be noted in the study report.

4.3.4. Assessment of cosmetic acceptability

In order to assess cosmetic acceptability, a specific questionnaire will be filled out by the volunteer. For each question, the volunteer will have to choose only one of the following answers: “completely agree”, “agree”, slightly disagree”, “disagree”. A percentage satisfaction will be calculated for each question from positive opinions (“completely agree” and “agree”). Cosmetic qualities relating to efficacy with a reported satisfaction rate ≥ 75 % will be recorded in the report and may be claimed by the sponsor.
The investigator may draw a general conclusion as to cosmetic acceptability using the following scale:

Percentage satisfaction calculated from the question “Your impression of the product is good”				
< 50 %	50 % - 59 %	60 % - 89 %	90 % - 99 %	100 %
Poor	**Average**	**Good**	**Very good***	**Excellent****

* From 15 volunteers analysed
** From 20 volunteers analysed

4.4. Adverse events

4.4.1. General details

The following are distinguished:
- events unrelated to the product;
- adverse effects reported by the volunteer: sensations of discomfort (tingling, tight sensation, itching, etc.), including the clinical signs (redness, dryness, small spots);
- adverse effects noted by the assessor: clinical reactions seen (erythema, oedema, roughness, desquamation, papules, etc.)

4.4.2. Recording and management of adverse effects

Any adverse effect reported by the volunteer or noted by the assessor will be managed and recorded using the current in-house procedure.

4.4.3. Intensity

In order to assess the intensity of an adverse effect, the assessor will use the following descriptions:
- very mild: felt very weakly by the volunteer, but not requiring treatment and not interfering with the volunteer’s everyday activities;
- mild: felt by the volunteer, but not requiring treatment and not interfering with the volunteer’s everyday activities;
- moderate: discomfort, possibly requiring treatment, but not interfering with the volunteer’s everyday activities;
- severe: very uncomfortable or even intolerable, requiring treatment and which may or may not interfere with the volunteer’s everyday activities.

4.4.4. Attributability

The following must be determined whenever an adverse effect occurs:
- whether the time between exposure and occurrence of the symptoms is compatible;
- whether the symptoms are compatible with the cosmetic use.

The investigator will endeavour to establish the causal relationship between the occurrence of an adverse effect and the investigational product using the following descriptions:

- excluded/nil: a simultaneous disease, a simultaneous treatment or any other known cause are responsible for the adverse event, or the time course is incompatible;
- doubtful: this relationship exists if the adverse event follows a chronological sequence which is unlikely from the time of administration of the product and/or the type of reaction seen is poorly compatible with the category of product, with no history of reproduction or the same reaction occurring after a rechallenge with the product; re-challenge with the product is not deemed necessary by the investigator to draw a conclusion;
- possible: this relationship exists when the adverse event follows a reasonable chronological sequence from the time of administration of the product, when development is mostly occasional and when the type of reaction seen is compatible with the category of product although no rechallenge was deemed necessary by the investigator or the same reaction was not reproduced after rechallenge with the product;
- probable: this relationship exists when the adverse event follows a reasonable chronological course from the time of administration of the product and when the type of reaction found is compatible with the product category, when rechallenged with the product produced a reaction which was not clearly the same but was still suggestive or re-challenge was not deemed necessary by the investigator to draw a conclusion;
- very likely: this relationship exists when the adverse event follows a reasonable chronological sequence from the time of administration of the product and when the type of reaction observed is compatible with the product category with a history of confirmation of the reaction on rechallenge.

4.4.5. Pregnancies:

Volunteers will not be included if they are suspected to be pregnant at inclusion.
If a volunteer is suspected to have become pregnant during the study, she will be excluded from the study. The cosmetic product will cease to be used as soon as the volunteer's pregnancy is known and the pregnancy will be monitored by the investigator until delivery.

4.5. Management in the event of exclusion

A volunteer may be excluded from the study for the following reasons:

- at his/her own request;
- on the decision of the investigator;
- following an adverse event;
- for administrative reasons.

In all cases, the sponsor will be informed of the exclusion and the reason for it. This will be clearly described in the study report. Volunteers excluded from the study will not be replaced.
If a volunteer is "lost to follow up", every efforts will be made to contact the volunteer and establish the corresponding reason.

4.6. Management in the event of protocol deviation

For each protocol deviation, the procedure to be followed is shown below:

Situation		Data included
Withdrawal		NO
Exclusion criterion during the study		NO
Failure to observe protocol	Major	NO
	Minor or acceptable	YES
Withdrawal from the study due to the product		YES
Withdrawal from the study not due to the product		NO
Volunteer incorrectly included		NO

All protocol deviations will be recorded in the report and the investigator will provide a decision as to its impact.
In emergency situations, the investigator will manage the volunteer medically following the appropriate procedure. The treatment and procedure will be notified to the sponsor as soon as possible.

4.7. Protocol amendment

Any change made to the protocol after the start of the study will be made in the form of an amendment.
Protocol amendments will be managed in the same way as the protocols.

5. LEGAL FRAMEWORK, ETHICAL AND LEGAL CONSIDERATIONS

5.1. Regulations

This study will be conducted in the spirit of the European directives on *Good Clinical Practice*. It has no direct therapeutic endpoint for the volunteer and will be conducted in accordance with the most recent recommendations of the World Medical Association (current version of the Declaration of Helsinki).

It does not fall within the scope of French law on the protection of people taking part in biomedical research. No information will therefore be submitted to the national file of people taking part in biomedical research without direct individual benefit and no opinion will be sought from an Ethics Committee. The spirit of Decree on application of this law will however be respected.

5.2. Confidentiality

All details concerning the state of health of volunteers and the results of clinical examinations undertaken before the study (for volunteer recruitment selection and admission) are subject to medical confidentiality requirements pursuant to Article 378 of the French penal code and the medical deontology code (Decree n° 95-1000 of 6 September 1995). These will, in no situation, be communicated to the sponsor with their identity.
All study documents containing confidential information about the volunteers will be archived in the study dossier in a sealed envelope.
In order to maintain the anonymity of volunteers taking part in the study, the volunteers will be identified by a four letter code containing the first two letters of their surname, followed by the first two letters of their forename. In addition, they will be allocated a number corresponding to their order of inclusion into the study.
The investigator and all people working in the study are bound by professional confidentiality with regard to the nature of the products studied, the study process, volunteers' data and the final results.

5.3. Insurance taken out by IDEA Clinic

The study will be covered by a liability insurance contract taken out by the sponsor covering studies on healthy volunteers.
The IDEA TESTS group has taken out an insurance contract guaranteeing the safety of volunteers.
Company name: COVEA RISKS.
Contract N°: 128 776 308
IDEA Clinic will ensure where appropriate that the subcontractor for the study has taken out appropriate insurance.

5.4. Quality management

5.4.1. Control of data

Each study dossier will be controlled by the IDEA Tests Group Quality Assurance Department or where applicable the Quality Assurance department of its subcontractors. This stage will confirm compliance of the study process with this protocol and with the in-house procedures for the IDEA Tests Group in the spirit of Good Clinical Practice. The final report will be audited by the IDEA Tests Group Quality Assurance department in order to guarantee that it accurately reflects the raw data generated and current procedures.

5.4.2. Qualification of staff

The investigator will ensure that staff taking part in the study possesses the competencies and accreditation approvals required to conduct the study.

5.5. ARCHIVING

The test facility will store documents concerning the study (final report, case report form, raw data) initially in its own archiving rooms. The study files will then be transferred to an approved archiving service company.

The study files will be stored for a period of 10 years for those studies on cosmetics. Beyond this time the data will be destroyed unless if specifically requested otherwise by the sponsor requesting that these be returned to it.

6. SIGNATURE

Caterina PAHOMI
Dermatologist
IDEA Clinic